Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. The Company's lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. Stemline's preclinical pipeline also includes SL-501 and SL-101, two next generation IL-3R-targeted compounds. The Company has also constructed a drug discovery platform StemScreen, and built an extensive intellectual property portfolio that includes some of the earliest patents in the CSC field.